Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.Ulrich Keilholz, Jérôme Fayette, Andrzej Kawecki et al.|Journal of Clinical Oncology|2018Cited by 5
Cytokine release syndrome and immune effector cell‑associated neurotoxicity syndrome in a melanoma patient treated with adjuvant pembrolizumabSebastián Ochenduszko, Ana García Feria, C. Françès et al.|Experimental and Therapeutic Medicine|2024Cited by 5